Current Medicinal Chemistry ( IF 4.1 ) Pub Date : 2021-05-01 , DOI: 10.2174/0929867327666200824110332 Parth Malik 1 , John R Hoidal 2 , Tapan K Mukherjee 2
Characterized by the abysmal 18% five year survival chances, non-small cell lung cancers (NSCLCs) claim more than half of their sufferers within the first year of being diagnosed. Advances in biomedical engineering and molecular characterization have reduced the NSCLC diagnosis via timid screening of altered gene expressions and impaired cellular responses. While targeted chemotherapy remains a major option for NSCLCs complications, delayed diagnosis, and concurrent multi-drug resistance remain potent hurdles in regaining normalcy, ultimately resulting in relapse. Curcumin administration presents a benign resolve herein, via simultaneous interception of distinctly expressed pathological markers through its pleiotropic attributes and enhanced tumor cell internalization of chemotherapeutic drugs. Studies on NSCLC cell lines and related xenograft models have revealed a consistent decline in tumor progression owing to enhanced chemotherapeutics cellular internalization via co-delivery with curcumin. This presents an optimum readiness for screening the corresponding effectiveness in clinical subjects. Curcumin is delivered to NSCLC cells either (i) alone, (ii) in stoichiometrically optimal combination with chemotherapeutic drugs, (iii) through nanocarriers, and (iv) nanocarrier co-delivered curcumin and chemotherapeutic drugs. Nanocarriers protect the encapsulated drug from accidental and non-specific spillage. A unanimous trait of all nanocarriers is their moderate drug-interactions, whereby native structural expressions are not tampered. With such insights, this article focuses on the implicit NSCLC curative mechanisms viz-a-viz, free curcumin, nanocarrier delivered curcumin, curcumin + chemotherapeutic drug and nanocarrier assisted curcumin + chemotherapeutic drug delivery.
中文翻译:
姜黄素治疗非小细胞肺癌的最新进展:多效性状和纳米载体辅助递送的推动力
非小细胞肺癌 (NSCLC) 的特点是 5 年生存率极低,为 18%,在被诊断的第一年内,超过一半的患者被治愈。生物医学工程和分子表征的进步通过对改变的基因表达和受损的细胞反应进行胆怯的筛查,减少了 NSCLC 的诊断。虽然靶向化疗仍然是非小细胞肺癌并发症的主要选择,但延迟诊断和并发多药耐药仍然是恢复正常的潜在障碍,最终导致复发。通过姜黄素的多效性和增强的肿瘤细胞内化化疗药物同时拦截明显表达的病理标志物,姜黄素给药在本文中呈现出良性解决方案。对 NSCLC 细胞系和相关异种移植模型的研究表明,由于通过与姜黄素共同递送增强化疗药物细胞内化,肿瘤进展持续下降。这为筛选临床受试者中的相应有效性提供了最佳准备。姜黄素可以 (i) 单独递送至 NSCLC 细胞,(ii) 与化疗药物在化学计量上最佳组合,(iii) 通过纳米载体,以及 (iv) 纳米载体共同递送姜黄素和化疗药物。纳米载体保护封装的药物免受意外和非特异性溢出。所有纳米载体的一个一致特征是它们的适度药物相互作用,从而不会篡改天然结构表达。有了这样的见解,本文重点介绍了隐性 NSCLC 的治疗机制,即